Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function
- PMID: 12756287
- DOI: 10.1242/jeb.00241
Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function
Abstract
The first step in metabolism of glucose (Glc) is usually phosphorylation, catalyzed by hexokinase. However, the Glc-6-P produced can then enter one or more of several alternative pathways. Selective expression of isozymic forms of hexokinase, differing in catalytic and regulatory properties as well as subcellular localization, is likely to be an important factor in determining the pattern of Glc metabolism in mammalian tissues/cells. Despite their overall structural similarity, the Type I, Type II and Type III isozymes differ in important respects. All three isozymes are inhibited by the product, Glc-6-P, but with the Type I isozyme, this inhibition is antagonized by P(I), whereas with the Type II and Type III isozymes, P(i) actually causes additional inhibition. Reciprocal changes in intracellular levels of Glc-6-P and P(i) are closely associated with cellular energy status, and it is proposed that the response of the Type I isozyme to these effectors adapts it for catabolic function, introducing Glc into glycolytic metabolism for energy production. In contrast, the Type II, and probably the Type III, isozymes are suggested to serve primarily anabolic functions, e.g. to provide Glc-6-P for glycogen synthesis or metabolism via the pentose phosphate pathway for lipid synthesis. Type I hexokinase binds to mitochondria through interaction with porin, the protein that forms channels through which metabolites traverse the outer mitochondrial membrane. Several experimental approaches have led to the conclusion that the Type I isozyme, bound to actively phosphorylating mitochondria, selectively uses intramitochondrial ATP as substrate. Such interactions are thought to facilitate coordination of the introduction of Glc into glycolysis, via the hexokinase reaction, with the terminal oxidative stages of Glc metabolism occurring in the mitochondria, thus ensuring an overall rate of Glc metabolism commensurate with cellular energy demands and avoiding excessive production of lactate. The Type II isozyme also binds to mitochondria. Whether such coupling occurs with mitochondrially bound Type II hexokinase in normal tissues, and how it might be related to the proposed anabolic role of this isozyme, remain to be determined. The Type III isozyme lacks the hydrophobic N-terminal sequence known to be critical for binding of the Type I and Type II isozymes to mitochondria. Immunolocalization studies have indicated that, in many cell types, the Type III has a perinuclear localization, the possible metabolic consequences of which remain unclear.
Similar articles
-
Structural determinants for the intracellular localization of the isozymes of mammalian hexokinase: intracellular localization of fusion constructs incorporating structural elements from the hexokinase isozymes and the green fluorescent protein.Arch Biochem Biophys. 1997 Sep 1;345(1):111-25. doi: 10.1006/abbi.1997.0241. Arch Biochem Biophys. 1997. PMID: 9281318
-
Functional organization of mammalian hexokinases: characterization of the rat type III isozyme and its chimeric forms, constructed with the N- and C-terminal halves of the type I and type II isozymes.Arch Biochem Biophys. 1997 Feb 15;338(2):183-92. doi: 10.1006/abbi.1996.9850. Arch Biochem Biophys. 1997. PMID: 9028870
-
Mitochondria and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit.Diabetes. 1996 Feb;45(2):113-26. doi: 10.2337/diab.45.2.113. Diabetes. 1996. PMID: 8549853 Review.
-
Residues putatively involved in binding of ATP and glucose 6-phosphate to a mammalian hexokinase: site-directed mutation at analogous positions in the N- and C-terminal halves of the type I isozyme.Arch Biochem Biophys. 1995 Aug 20;321(2):413-20. doi: 10.1006/abbi.1995.1412. Arch Biochem Biophys. 1995. PMID: 7646067
-
[Identification and characterization of hexokinase isozyme predominantly expressed in malignant tumor cells].Yakugaku Zasshi. 2000 Aug;120(8):657-66. doi: 10.1248/yakushi1947.120.8_657. Yakugaku Zasshi. 2000. PMID: 10946615 Review. Japanese.
Cited by
-
O-GlcNAcylation of hexokinase 2 modulates mitochondrial dynamics and enhances the progression of lung cancer.Mol Cell Biochem. 2024 Nov 4. doi: 10.1007/s11010-024-05146-2. Online ahead of print. Mol Cell Biochem. 2024. PMID: 39496915
-
A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer.Oncogene. 2016 Nov 24;35(47):6132-6142. doi: 10.1038/onc.2016.150. Epub 2016 May 2. Oncogene. 2016. PMID: 27132509 Free PMC article.
-
Natural products targeting glycolytic signaling pathways-an updated review on anti-cancer therapy.Front Pharmacol. 2022 Oct 20;13:1035882. doi: 10.3389/fphar.2022.1035882. eCollection 2022. Front Pharmacol. 2022. PMID: 36339566 Free PMC article. Review.
-
Synthesis and Primary Activity Assay of Novel Benitrobenrazide and Benserazide Derivatives.Molecules. 2024 Jan 29;29(3):629. doi: 10.3390/molecules29030629. Molecules. 2024. PMID: 38338374 Free PMC article.
-
Effect of delay in transportation of extracellular glucose into cardiomyocytes under diabetic condition: a study through mathematical model.J Biol Phys. 2020 Sep;46(3):253-281. doi: 10.1007/s10867-020-09551-8. Epub 2020 Jun 25. J Biol Phys. 2020. PMID: 32583238 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous
